The agency wants applicants to demystify their algorithms and provide specific details about what the models do, how they’re ...

Stay updated on the volatile share price of Recursion, a biotech company with a maturing pipeline and potential for growth ...

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

A middle school student in Chicago made headlines by uncovering a remarkable medical breakthrough hidden in a surprising ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the company's growth, ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Dr. Buchanan will helm Belharra's research organization as the company progresses its lead immunology and oncology programs, advances activities with its pharma collaborators, and enriches its ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

UK Biobank's proteomics study will measure 5,400 proteins in 600,000 samples, tracking changes over mid-to-late life. By ...